Abstract
Introduction

Blocking the angiogenic cascade is an important objective in limiting tumour growth, ocular neovascularization or arthritis; however, a wide range of applications in the field of reconstructive surgery require the induction of angiogenesis. A mended vascular network and improved blood flow will be beneficial to all kinds of flap designs and chronic wounds. Necrosis in critically perfused tissue
could be minimized and targeted angiogenesis will result in greater liberty of flap design [1] .
Impaired wound healing is a common post-operative complication and insufficient supply of oxygen and nutrients to the tissue impedes the physiological phases of healing. The formation of necrosis additionally deteriorates the nutrient supply, averts the formation of granulation tissue and promotes the colonization of bacteria. An improved vascular network would not only accelerate wound healing but also reduce the necessity of frequent surgical interventions. Methods to promote angiogenesis and improve local perfusion have been investigated for many years, and of the different growth factors involved VEGF has proved to be among the most promising. The clinical deployment of VEGF gene therapy in phase II clinical trials is so far limited to the treatment of myocardial
Non-viral VEGF 165 , Riccardo E. Giunta a, * ischemia and peripheral arterial disease [2] [3] [4] [5] [6] [7] [8] [9] . In the field of reconstructive surgery we consider VEGF gene therapy pre-treatment of local flaps to increase flap dimensions the most promising application at this time. We were able to increase the lengthto-width ratio in a random-pattern-flap model in the rats from 2:1 to 3:1 using an adenovirus encoding VEGF165 [1] . [10] . The concentration of the vector in the target area and accumulation can both be enhanced by magnetofection methods [11] . In addition, magnetofection results in an enhanced dose-response relationship with a smaller amount of DNA required for sufficient gene expression [12] .
The latest modification represents the combination of magnetic drug targeting and microsphere technology [13, 14] . Clinically, microspheres (or microbubbles) are applied as ultrasound contrast agents and experimentally as drug carriers and gene vectors [13, 15] [14] . In this study, we used acoustically active magnetic lipospheres containing the VEGF165 cDNA in a lipid shell. We investigated the potential of magnetofection of the VEGF165 gene on the survival and perfusion of the well-established oversized random-pattern-flap model in the rats [1, 16, 17] and compared the results to our previous findings using an adenoviral vector construct [1] . We evaluated the method with respect to the significance of applied magnetic field and ultrasound. Additionally we assessed VEGF-protein concentration in target tissue and analysed microvessel density and vessel diameter. [1, 16, 19, 20] 
Material and methods
Magnetic lipospheres (magnetobubbles)
Magnetic applicator characteristics
. Perfusion of the abdominal region of the rat is similar to that of the human and thus this model can be modified to simulate perforator-flaps (DIEP-flap) and musculocutaneous flaps (TRAM).
Fig. 3 (A-D) Experimental set-up (a) and magnetic applicator characteristics (b-d). The magnetic field was applied using a magnetic applicator composed of six NeFeB disk magnets (d ϭ 20 mm, h ϭ 5 mm) and three steel cylinders (d ϭ 20 mm, h ϭ 120 mm) as shown in a photo a and scheme b. The magnetic induction z-component values Bz were measured in a 1 mm grid in a plane (x, y) parallel to and at different distances z from the working surface of the applicator and used to calculate z-component of a magnetic field gradient in z-direction dB/dz (shown in graphs c and d for z ϭ 2 mm).
In a 'working area' up to 2-3 mm over the surface of the applicator magnetic field induction and its derivative were found to be predominantly higher than 0.2 T and 0.05 T/mm, respectively.
Magnetobubble injection
The treatment (magnetobubble magnetofection of the VEGF165 gene or controls) was carried out 7 days before surgery (Table 1) . This interval between gene therapy and surgery yielded best results in our previous angiogenesis research [1] . Prior to injection of vectors, the abdominal skin was shaved under anaesthesia from sternum to the pubic region. In groups A1-A3, P1 and D1 a total of 200 l volume of magnetobubbles containing VEGF165 cDNA was injected subcutaneously in four aliquots of 50 l each into the distal half of the overdimensioned future flap (Fig. 4A) (Fig. 4B) . This incubation time was found to be sufficient for a successful transfection [12] . In the 'working area' 2-3 mm below the surface of the applicator magnetic induction and its derivative are predominantly Ͼ0.2 T and Ͼ50 T/m, respectively. After 5 min. under the magnetic field, ultrasound was applied additionally (groups A1, A3, A4, P1, D1) for a total of 5 min. to the four injection spots (Fig. 4C) 
Surgical technique
Surgery was scheduled 7 days after microbubble administration. After depilation of the anterior abdominal wall and marking of the flap design, the flap was raised in the subcutaneous layer between skin and muscle. All perforating vessels reaching the skin from the inferior and superior epigastric artery were carefully divided. After haemostasis was obtained, the flap was repositioned and sutured back into place with interrupted sutures.
VEGF 165 ELISA
In groups P1 and P2 (control) the skin flaps and underlying muscle were harvested 7 days after magnetobubble administration and immediately shock-frozen in liquid nitrogen. Both skin and muscle specimens were divided into the proximal and distal halves in analogy to the flap design with the distal half being critically perfused and bearing the injection sites. © 2008 The Authors Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
P1 (n ϭ 6) VEGF-bubbles ϩ magnet ϩ ultrasound 7 days pre-OP VEGF-ELISA; 7 days after therapy P2 (n ϭ 6) Ϫ Controls Ϫ NaCl 7 days pre-OP VEGF-ELISA; 7 days after therapy D1 (n ϭ 2) VEGF-bubbles ϩ magnet ϩ ultrasound 7 days pre-OP Assessment of microvessel density, assessment of vessel diameter; 7 days after therapy D2 (n ϭ 2) Ϫ Controls Ϫ NaCl 7 days pre-OP Assessment of microvessel density, assessment of vessel diameter; 7 days after therapy
Indocyanine green laser-fluoroscopy
ICG (Pulsion Medical Systems AG, Munich, Germany) is a tricarbocyanine dye that binds almost completely to globulins and is exclusively distributed in the intravascular space. ICG has a normal plasma half-life of 3 to 4 min., is not metabolized in the body and is eliminated exclusively through the liver and excreted into the bile. ICG-fluorescence was induced and recorded using a laser-fluorescence imaging device (IC-
Measurement of flap size
In groups A1-A5, digital images were taken perpendicular to the flap 7 days after surgery. Pictures were analysed using NIH Image Software (National Institutes of Health, MD, USA). 
Microvessel density
Vessel diameter
Vessel diameter and morphometry were assessed by means of corrosion casting [23, 24] . (Fig. 5A and B) .
The VEGF protein concentration in the underlying muscle did not differ statistically significant (P Ͼ 0.05), thus indicating a locally restricted effect of the therapy (Fig. 6A and B) (Fig. 7) . (Figs. 8A and B, 9 ). Figure 10A creates an impression of increased microvessel density, but differences in both layers were statistically not significant (P Ͼ 0.05) (Fig. 10B) 
Measurement of flap size
Microvessel density
Vessel diameter
Vessel diameter and morphometry were assessed by means of corrosion casting 7 days after VEGF-microbubble magnetofection (group D1) and in controls (group D2) (Fig. 10A ). 
It turned out that only the combination of both resulted in signifi
